Whereas permanent paths into the intraocular space created by implants are used in refractive glaucoma (Ahmed Glaucoma Valve; New World Medical, Inc., Rancho Cucamonga, CA, USA35,36 and Baerveldt Glaucoma Implants; Johnson & Johnson Vision, Santa Ana, CA, USA35,36), and more recently in an effort to prolong intravitreal anti-VEGF release (Port Delivery System, PDS, Susvimo; Genetech, South San Francisco, CA, USA37), major risks, that is, increased risk for endophthalmitis, retinal detachment, and suprachoroidal hemorrhage have been reported.35 This evidence concerns the gene VEGFA and retinal detachment.